Is GlaxoSmithKline plc a good investment?
GlaxoSmithKline plc (GSK) is currently trading at 50.45 USD.
Market analysts have a consensus price target of 59.12 USD.
This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 17.98.
This valuation is generally in line with the broader market.
Earnings Schedule:
GlaxoSmithKline plc is expected to release its next earnings report on Feb. 3, 2027.
The market consensus estimate for Forward EPS is 4.96.
For income investors, GlaxoSmithKline plc pays a dividend yield of 3.60%.
With a payout ratio of 62%, the dividend appears
sustainable.
Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
Community Discussion